Table 3.
Cost-effectiveness analysis of case finding strategies.
| Total Costs (USD) | Total DALYs averted | Incremental Costs (USD) | Incremental DALYS averted | ICER (USD per DALY) | |
|---|---|---|---|---|---|
| Baseline, standard care | 0 | 0 | na | na | na |
| School Screening | 278,303 | 178 | Weakly dominated | ||
| Door-to-Door | 2,304,941 | 11,669 | Weakly dominated | ||
| Eye Camps | 6,826,524 | 47,599 | 6,826,524 | 47,599 | 143 (95% CI: 93-251) |
| Vision Centers | 12,293,868 | 68,435 | 5,467,344 | 20,835 | 262 (95% CI: 175-431) |
Notes. Costs represent societal costs of operating each intervention from 1 April 2019 to 30 March 2020. Costs are the sum of case finding and treatment initiation costs, costs of spectacles and cataract surgery and, patient costs to access treatment. DALYs averted are estimated from administrative data on number of spectacles provided and cataract surgeries performed. DALYs and costs are discounted at a rate of 3% (Supplementary Material S6). Confidence intervals estimated by varying parameters across 10,000 Monte Carlo simulations (Supplementary Material S3 and S6).